Author Question: A client who is at 32 weeks' gestation is determined to be at high risk for ABO incompatibility. ... (Read 71 times)

kellyjaisingh

  • Hero Member
  • *****
  • Posts: 540
A client who is at 32 weeks' gestation is determined to be at high risk for ABO incompatibility. Which intervention should the nurse anticipate implementing?
 
  1. Intramuscular administration of 300 mcg of Rh immune globulin (RhoGAM).
  2. Obtain an antibody screen (indirect Coombs test) to determine whether the client has developed isoimmunity.
  3 Note the potential for ABO incompatibility and plan to carefully assess the neonate for the development of hyperbilirubinemia.
  4. Notify the primary care provider and document the potential need for treatment of fetal hemolytic anemia in the baby after delivery.

Question 2

The nurse is preparing teaching on maternalfetal ABO incompatibility for antepartum clients. Which statement should the nurse include in the teaching information?
 
  1. In most cases, ABO incompatibility is limited to type A mothers with a type B or O fetus.
  2. In most cases, ABO incompatibility is limited to type O mothers with a type A or B fetus.
  3. ABO incompatibility occurs as a result of the fetal serum antibodies present and interaction between the antigen sites on the maternal red blood cells (RBCs).
  4. Group A infants, because they have no antigenic sites on the red blood cells (RBCs), are never affected regardless of the mother's blood type.


kswal303

  • Sr. Member
  • ****
  • Posts: 316
Answer to Question 1

3
Explanation:
1. RhoGAM is administered to prevent sensitization after exposure to Rh-positive blood.
2. An antibody screen (indirect Coombs test) is done to determine whether an Rh-negative woman is sensitized (has developed isoimmunity) to the Rh antigen.
3. Unlike the situation with Rh incompatibility, antepartum treatment of ABO incompatibility is not warranted because it does not cause severe anemia. As part of the initial assessment, however, the nurse should note whether the potential for an ABO incompatibility exists in order to alert healthcare providers to the need for carefully assessing the newborn for the development of hyperbilirubinemia.
4. Unlike the situation with Rh incompatibility, antepartum treatment of ABO incompatibility is not warranted because it does not cause severe anemia.

Answer to Question 2

2
Explanation:
1. In most cases, ABO incompatibility is limited to type O mothers with a type A or B fetus. The group B fetus of a group A mother and the group A fetus of a group B mother are only occasionally affected.
2. In most cases, ABO incompatibility is limited to type O mothers with a type A or B fetus. The group B fetus of a group A mother and the group A fetus of a group B mother are only occasionally affected.
3. The incompatibility occurs as a result of the maternal antibodies present in her serum and interaction between the antigen sites on the fetal red blood cells (RBCs).
4. Group O infants, because they have no antigenic sites on the red blood cells (RBCs), are never affected regardless of the mother's blood type.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

Before a vaccine is licensed in the USA, the Food and Drug Administration (FDA) reviews it for safety and effectiveness. The CDC then reviews all studies again, as well as the American Academy of Pediatrics and the American Academy of Family Physicians. Every lot of vaccine is tested before administration to the public, and the FDA regularly inspects vaccine manufacturers' facilities.

Did you know?

In women, pharmacodynamic differences include increased sensitivity to (and increased effectiveness of) beta-blockers, opioids, selective serotonin reuptake inhibitors, and typical antipsychotics.

Did you know?

Between 1999 and 2012, American adults with high total cholesterol decreased from 18.3% to 12.9%

Did you know?

Blastomycosis is often misdiagnosed, resulting in tragic outcomes. It is caused by a fungus living in moist soil, in wooded areas of the United States and Canada. If inhaled, the fungus can cause mild breathing problems that may worsen and cause serious illness and even death.

Did you know?

The FDA recognizes 118 routes of administration.

For a complete list of videos, visit our video library